Safe and effective long-duration therapy in wet AMD treatment could be the solution to increasing patient adherence. Are we on the brink of a major breakthrough? Carl Danzig, MD, reviews the phase 2 STAIRWAY study, which evaluated the safety and efficacy of faricimab (Genentech/Roche) for the treatment of wet AMD, and previews the coming phase 3 trials TENAYA and LUCERNE.

This editorially independent podcast is supported with advertising.